Still, Gonzalez says Americans should not get too excited about the strong health care indicators, despite the bright — albeit short-term — investment and employment opportunities.
"The truth is on both sides," said Gonzalez. "Clearly, people are living longer. At the same time, there are more types of treatment available and new drugs that are costly to develop. Some of the costs come through increased profit, but over a long period of time, consumers, patients, Medicaid and Medicare absorb the costs.
"We are walking a thin line."